Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Outlines

https://doi.org/10.22037/ijpr.2021.114749.15018

Synthesis and Decarboxylation of Functionalized 2-Pyridone-3-carboxylic Acids and Evaluation of their Antimicrobial Activity and Molecular Docking

Author(s):
Elmira Meghrazi AhadiElmira Meghrazi Ahadia, Homa AzizianHoma Azizianb, Vaezeh Fathi VavsariVaezeh Fathi Vavsaria, Atousa AliahmadiAtousa Aliahmadic, Zeinab ShahsavariZeinab Shahsavaric, Hamid R. BijanzadehHamid R. Bijanzadehd, Saeed BalalaieSaeed Balalaiea, e,*
aPeptide Chemistry Research Institute, K. N. Toosi University of Technology, Tehran, Iran.
bDepartment of Medicinal Chemistry, School of Pharmacy, International Campus, Iran University of Medical Sciences, Tehran, Iran.
cMedicinal Plant and Drug Research Institute, Shahid Beheshti University, Tehran, Iran.
dDepartment of Environmental Sciences, Faculty of Natural Resources and Marine Sciences, Tarbiat Modares University, Tehran, Iran.
eMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
IJ Pharmaceutical Research:Vol. 20, issue 3; 456-475
Published online:Jul 31, 2021
Article type:Original Article
Received:Nov 30, 2020
Accepted:May 31, 2021
How to Cite:Meghrazi Ahadi E, Azizian H, Fathi Vavsari V, Aliahmadi A, Shahsavari Z, et al. Synthesis and Decarboxylation of Functionalized 2-Pyridone-3-carboxylic Acids and Evaluation of their Antimicrobial Activity and Molecular Docking. Iran J Pharm Res. 2021;20(3):e124309. doi: https://doi.org/10.22037/ijpr.2021.114749.15018

Abstract

Keywords
Multicomponent reactions; Antibiotics
2-Pyridone
Decarboxylation reaction
Induced fit docking
ADME properties
Molecular dynamic

Introduction

Designing new antibacterial agents, especially the selective ones, has become urgent, important and challenging research because of the antibiotic resistance, the appearance of resistant bacteria, and the increase of death as a result of infections (1).
The 2-pyridone motif is the core of many vital bioactive compounds and medicines, such as Pirfenidone and Flourofenidone, and easy preparation of pyridines functionalized at specific positions is important to synthetic and medicinal chemistry (2, 3). 2-Pyridones are mainly inspiring substrates for the synthesis of antimicrobial (4), antifungal (5), antiviral (6), anti-Alzheimer (7), anti-inflammatory (8), and cardiotonic (9) agents. Several remarkable antimicrobial agents consist of the 2-pyridone ring have been reported such as ABT-719, A-78830 (10-12), curlicide FN075 (13, 14), and nybomycin (15). Moreover, the 2-salicyloyl scaffold is the common potent moiety in the structure of many pharmacological and biologically active natural products such as flavonoid (16), isopestacin (17), pyrrolomycin C (18), and paenol (19) having potent antimicrobial activity.
These encouraging results led us to design a new scaffold consist of both 2-salicyloyl and 2-pyridones moiety through molecular hybridization strategy to develop a new antibacterial agent (Figure 1).
In this way, designing new structures comprising 2-pyridone is attractive research since by introducing substituents on different positions of its structure, the bioactivity may be changed. Moreover, substituted 2-pyridones have been employed as synthons for the preparation of numerous valuable N-rich heterocycles, including azachromones (20), quinoline, quinolone (21) and so on.
Various methodologies have been published for the preparation of 2-pyridones (22-24). Based on our experience, designing innovative synthetic routes to introduce carboxylic acid, hydroxybenzoyl, and N-aryl substituents in the 2-pyridone motif is highly preferred. Such ideal synthesis is achievable through the three-component reaction between 3-formylchromone, primary amines, and Meldrum’s acid in our laboratory (25). Due to its productivity in the preparation of new organic derivatives, decarboxylation reaction has been considered extensively among chemists. In many cases, by introducing substituents on rings, decarboxylation is accomplished to achieve the desired products. In this regard, decarboxylation methodologies have been extensively advanced (26, 27). Gooβen is the leader of this progress who worked on the Cu-catalyzed decarboxylative coupling reactions to form biaryls (28-31). So far, various catalysts have been used for the decarboxylation process, including Cu(II) (29), Pd(II) (32), Ag(I) (33), and Ni(II) (34). Metal catalysis, long reaction time, difficulties in separation of catalyst, and purification of products are some drawbacks of these methods. In some cases, decarboxylation is promoted by some functional groups in the same structure (35).
We wish to report, herein, the preparation, evaluation of its antimicrobial properties, and molecular docking of a library of 2-pyridone-3-carboxylic acids and their decarboxylated derivatives using potassium carbonate in toluene (Scheme 1). Furthermore, in silico induced fit docking and molecular dynamic calculations were completed to study the spatial conformation, orientation, and interactions of these structures over S.aureus DNA gyrase.

Experimental

General
All organic reactions were done under the air atmosphere. Commercially available substances were procured in reagent grades with high purity. Thin-layer chromatography (TLC) was aluminum plates coated with silica gel 60-F254, and the reaction progress was monitored by it under UV light of 254 nm for detection. Flash column chromatography was filled with silica gel 63-200 mesh and employed to purify products 5a-o. The melting point was presented by the Electrothermal 9100 apparatus. 1H and 13C NMR spectroscopy were documented on a Bruker 600, 400, 300 MHz and 150, 100, 75 MHz, respectively. Chemical shifts (δ) of 1H and 13C NMR spectra were prepared as ppm, and coupling constants (J) have been reported in Hertz (Hz). High-resolution mass (ESI-HRMS) was obtained by Agilent Q-TOF LC-MS spectrometer.
General process of the 4a-p synthesis
Products 4a-p were prepared by the reported procedure (25).
1-benzyl-5-(2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4a)
Yellow solid, mp 199-200 ℃, yield 86%; 1H NMR (400 MHz, DMSO-d6): δH = 13.51 (s, 1H, COOH), 10.43 (s, 1H, OH), 8.93 (d, J = 2.6 Hz, 1H, H-6-py), 8.51 (d, J = 2.5 Hz, 1H, H-4-py), 7.46 (t, J = 7.7 Hz, 1H, H-Ar), 7.41 – 7.31 (m, 6H, H-Ar), 7.02 (d, J = 8.2 Hz, 1H, H-Ar), 6.97 (t, J = 7.7 Hz, 1H, H-Ar), 5.40 (s, 2H, CH2N); 13C NMR (100 MHz, DMSO-d6): δC = 191.4, 164.9, 163.0, 156.3, 149.1, 144.8, 135.9, 133.9, 130.7, 129.2, 128.5, 128.4, 124.8, 120.0, 118.8, 117.2, 117.1, 53.6; LCMS-ESI (m/z) Calcd. for C20H16NO5 [M+H]+: 350.3500; found, 350.3.
5-(2-hydroxybenzoyl)-2-oxo-1-(prop-2-yn-1-yl)-1,2-dihydropyridine-3-carboxylic acid (4e)
Yellow solid, mp 135-136 ℃, yield 78%; 1H NMR (600 MHz, CDCl3): δH = 13.34 (s, 1H, COOH), 11.33 (s, 1H, OH), 8.88 (d, J = 2.0 Hz, 1H, H-6-py), 8.65 (d, J = 2.0 Hz, 1H, H-4-py), 7.56 (t, J = 7.8 Hz, 1H, H-Ar), 7.49 (d, J = 7.8 Hz, 1H, H-Ar), 7.10 (d, J = 8.4 Hz, 1H, H-Ar), 6.95 (t, J = 7.8 Hz, 1H, H-Ar), 4.95 (d, 2H, J = 2.6 Hz, CH2N), 2.73 (t, J = 2.7 Hz, 1H, HC≡C); 13C NMR (151 MHz, CDCl3): δC = 193.8, 163.6, 163.2, 162.9, 145.6, 144.3, 137.3, 131.5, 119.5, 119.4, 119.1, 118.1, 117.0, 74.1, 79.1, 39.8; HRMS-ESI (m/z) Calcd. for C16H12NO5 [M+H]+: 298.0610; found, 298.0630.
5-(2-hydroxybenzoyl)-2-oxo-1-((1-phenyl-1H-1,2,3-triazol-5-yl)methyl)-1,2dihydro­pyridine-carboxylic acid (4g)
White solid, mp 186-187 ℃, yield 69%; 1H NMR (300 MHz, CDCl3): δH = 13.53 (s, 1H, COOH), 11.31 (s, 1H, OH), 8.85 (d, J = 2.2 Hz, 1H, H-6-py), 8.68 (d, J = 2.1 Hz, 1H, H-4-py), 8.28 (s, 1H, CH-triazol), 7.73 (d, J = 7.8 Hz, 2H, H-Ar), 7.45 – 7.59 (m, 5H, H-Ar), 7.08 (d, J = 8.2 Hz, 1H, H-Ar), 6.96 (t, J = 7.6 Hz, 1H, H-Ar), 5.52 (s, 2H, CH2N); 13C NMR (75 MHz, CDCl3): δC = 193.8, 163.9, 163.7, 162.8, 146.4, 145.7, 140.9, 137.2, 136.6, 131.7, 129.9, 129.4, 122.6, 120.7, 119.6, 119.5, 118.9, 119.0, 117.4, 45.9; HRMS-ESI (m/z) Calcd. for C22H16N4NaO5 [M+Na]+: 439.1018 ; found, 439.1013.
1-(3,4-dimethoxyphenethyl)-5-(2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4h)
Yellow solid, mp 109-111 ℃, yield 74%; 1H NMR (300 MHz, CDCl3): 13.72 (s, 1H, COOH), 11.23 (s, 1H, OH), 8.83 (d, J = 2.5 Hz, 1H, H-6-py), 7.68 (d, J = 2.5 Hz, 1H, H-4-py), 7.46-7.53 (m, 1H, H-Ar), 7.02 (d, J = 8.3 Hz, 1H, H-Ar), 6.87 (dd, J = 8.1, 1.8 Hz, 1H, H-Ar), 6.83 (d, J = 7.7 Hz, 1H, H-Ar), 6.77 – 6.80 (m, 1H, H-Ar), 6.70 (d, J = 1.8 Hz, 1H, H-Ar), 6.58 (dd, J = 8.1, 1.8 Hz, 1H, H-Ar), 4.36 (t, J = 6.5 Hz, 2H, CH2N), 3.84 (s, 3H, OMe), 3.82 (s, 3H, OMe), 3.13 (t, J = 6.5 Hz, 2H, CH2Ph); 13C NMR (75 MHz, CDCl3): δC = 193.6, 164.1, 163.8, 162.7, 149.7, 148.5, 146.3, 145.4, 137.0, 131.2, 128.6, 121.3, 119.3, 118.9, 118.3, 118.0, 117.4, 111.8, 111.7, 56.0, 55.9, 54.1, 33.9; ; HRMS-ESI (m/z) Calcd. for C23H22NO7 [M+H]+ :424.1397; found, 424.1391.
5-(2-hydroxybenzoyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid (4i)
Yellow solid, mp 207-209 ℃, yield 65%; 1H NMR (600 MHz, CDCl3): δH = 13.44 (s, 1H, COOH), 11.31 (s, 1H, OH), 8.95 (d, J = 2.2 Hz, 1H, H-6-py), 8.28 (d, J = 2.1 Hz, 1H, H-4-py), 7.52 – 7.63 (m, 5H, H-Ar), 7.44 (d, J = 7.4 Hz, 2H, H-Ar), 7.09 (d, J = 8.7 Hz, 1H, H-Ar), 6.96 (t, J = 7.6 Hz, 1H, H-Ar); 13C NMR (151 MHz, CDCl3): δC = 193.9, 163.9, 163.8, 162.9, 146.3, 145.9, 138.4, 137.3, 131.5, 130.5, 130.0, 126.1, 119.6, 119.4, 119.1, 118.1, 117.8; HRMS-ESI (m/z) Calcd. for C19H14NO5 [M+H]+: 336.0860; found, 336.0868.
1-benzyl-5-(5-fluoro-2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4j)
Yellow solid, mp 186-187 ℃, yield 67%; 1H NMR (600 MHz, CDCl3): δH = 13.57 (s, 1H, COOH), 10.96 (s, 1H, OH), 8.83 (d, J = 2.4 Hz, 1H, H-6-py), 8.18 (d, J = 2.5 Hz, 1H, H-4-py), 7.89 (dd, J = 7.9, 3.0 Hz, 1H, H-Ar), 7.52-7.55 (m, 1H, H-Ar), 7.39 – 7.48 (m, 3H, H-Ar), 7.37 (d, J = 7.1 Hz, 1H, H-Ar), 7.29 – 7.24 (m, 1H, H-Ar), 7.07 – 7.00 (m, 1H, H-Ar), 5.32 (s, 2H, CH2N); 13C NMR (151 MHz, CDCl3): δC = 193.0, 163.9, 162.2, 161.1, 158.9, 154.7 (1JCF = 241.0 Hz), 147.0, 144.8, 133.3, 129.6, 128.8, 122.9 (2JCF = 25.4 Hz), 120.5 (3JCF = 7.5 Hz), 118.7, 117.7, 117.0, 116.2 (2JCF = 24.0 Hz), 54.0; HRMS-ESI (m/z) Calcd. for C20H15FNO5 [M+H]+: 368.0942; found, 368.0933.
1-allyl-5-(5-fluoro-2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4k)
Yellow solid, mp 122-123 ℃, yield 70%; 1H NMR (600 MHz, CDCl3): δH = 13.52 (s, 1H, COOH), 10.99 (s, 1H, OH), 8.83 (d, J = 2.1 Hz, 1H, H-6-py), 8.22 (d, J = 2.0 Hz, 1H, H-4-py), 7.30 (dt, J = 7.1, 2.8 Hz, 1H, H-Ar), 7.14 (dd, J = 8.3, 2.8 Hz, 1H, H-Ar), 7.07 (dd, J = 9.1, 4.4 Hz, 1H, H-Ar), 5.90-6.00 (ddt, J = 16.6, 10.2, 6.2 Hz, 1H, =CH), 5.48 (d, J = 10.2 Hz, 1H, =CH cis), 5.40 (d, J = 17.1 Hz, 1H, =CH trans), 4.78 (d, J = 6.1 Hz, 2H, CH2N); 13C NMR (151 MHz, CDCl3): δC = 193.1, 163.8, 163.7, 159.0, 154.8 (1JCF = 240 Hz), 145.5, 144.8, 129.9, 124.9 (2JCF = 23.6 Hz), 122.1 , 120.6 (3JCF = 6 Hz), 118.8, 117.7 (3JCF = 6 Hz), 117.5, 116.3 (2JCF = 24 Hz), 52.9; HRMS-ESI (m/z) Calcd. For Calcd. for C16H13FNO5 [M+H]+: 318.0547; found, 318.0505.
1-cyclohexyl-5-(5-fluoro-2-hydroxybenz oyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4l)
Yellow solid, mp 135-136 ℃, yield 79%; 1H NMR (600 MHz, CDCl3): δH = 13.77 (s, 1H, COOH), 11.01 (s, 1H, OH), 8.79 (s, 1H, H-6-py), 8.28 (s, 1H, H-4-py), 7.27 – 7.32 (dt, J = 7.1, 2.9 Hz, 1H, H-Ar), 7.14 (dd, J = 8.4, 2.9 Hz, 1H, H-Ar), 7.07 (dd, J = 9.1, 4.4 Hz, 1H, H-Ar), 4.91 – 4.98 (m, 1H, CH-cyclohexyl), 2.05 – 2.10 (m, 2H, H-cyclohexyl), 1.98 – 1.99 (m, 2H, H-cyclohexyl), 1.76– 1.82 (m, 2H, H-cyclohexyl), 1.52 – 1.58 (m, 4H, H-cyclohexyl); 13C NMR (151 MHz, CDCl3): δC = 193.5, 164.2, 163.7, 162.7, 158.9, 154.9 (1JCF = 241.0 Hz), 147.0, 144.0, 124.7 (2JCF = 23.5 Hz), 120.5 (3JCF = 6 Hz), 118.7, 117.8 (3JCF = 6 Hz), 116.3 (2JCF = 23.9 Hz), 57.3, 32.6, 25.6, 25.0;; HRMS-ESI (m/z) Calcd. for C19H19FNO5 [M+H]+: 360.1242; found, 360.1251.
5-(5-fluoro-2-hydroxybenzoyl)-2-oxo-1-(1-phenylethyl)-1,2-dihydropyridine-3-carboxylic acid (4m)
Yellow solid, mp 151-154 ℃, yield 63%; 1H NMR (300 MHz, CDCl3): δH = 13.64 (s, 1H, COOH), 10.99 (s, 1H, OH), 8.82 (d, J = 2.5 Hz, 1H, H-6-py), 8.03 (d, J = 2.5 Hz, 1H, H-4-py), 7.34 – 7.51 (m, 5H, H-Ar), 7.19 – 7.30 (m, 1H, H-Ar), 7.02 (dd, J = 9.1, 4.5 Hz, 1H, H-Ar), 6.83 (dd, J = 8.4, 2.9 Hz, 1H, H-Ar), 6.50 (q, J = 6.9 Hz, 1H, CHN), 1.87 (d, J = 7.0 Hz, 3H, CH3CH); 13C NMR (75 MHz, CDCl3): δC = 193.0, 163.9, 163.7, 158.9, 154.7(1JCF = 241 Hz), 144.4, 143.4, 137.4, 129.7, 129.6, 127.5, 124.6 (2JCF = 23.2 Hz), 120.4 (3JCF = 7.5 Hz), 118.6, 117.7, 117.6, 116.1(2JCF = 23.2 Hz), 56.1, 19.0; LCMS-ESI (m/z) Calcd. for C21H17FNO5 [M+H]+: 382.360 ; found, 382.2.
1-benzyl-5-(2-hydroxy-4-methoxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4n)
Brown solid, mp 106-107 ℃, yield 57%; 1H NMR (300 MHz, CDCl3): δH = 13.42 (s, 1H, COOH), 12.04 (s, 1H, OH), 8.80 (d, J = 2.5 Hz, 1H, H-6-py), 8.19 (d, J = 2.5 Hz, 1H, H-4-py), 7.24 – 7.48 (m, 6H, H-Ar), 6.50 (d, J = 2.5 Hz, 1H, H-Ar), 6.42 (dd, J = 9.0, 2.5 Hz, 1H, H-Ar), 5.33 (s, 2H, CH2N), 3.86 (s, 3H, OMe); 13C NMR (75 MHz, CDCl3): δC = 192.1, 166.9, 166.2, 164.2, 163.9, 145.1, 145.0 , 133.7, 133.3, 129.5, 129.4, 128.7, 119.7, 117.2, 112.0, 108.3, 101.6, 55.8, 53.9; HRMS-ESI (m/z) Calcd. for C21H18NO6 [M+H]+: 380.1127; found, 380.1130.
5-(2-hydroxy-4-methoxybenzoyl)-2-oxo-1-vinyl-1,2-dihydropyridine-3-carboxylic acid (4o)
Brown solid, mp 103-106 ℃, yield 52%; 1H NMR (300 MHz, DMSO-d6): δH = 13.77 (s, 1H, COOH), 10.98 (s, 1H, OH), 8.65 (d, J = 2.6 Hz, 1H, H-6-py), 8.48 (d, J = 2.5 Hz, 1H, H-4-py), 7.46 (d, J = 8.6 Hz, 1H, H-Ar), 6.50 – 6.59 (m, 2H, H-Ar), 5.96 – 6.07 (m, 1H, CHCH2), 5.27 (d, J = 9.4 Hz, 1H, =CH cis), 5.23 (d, J = 16.4 Hz, 1H, =CH trans), 4.79 (d, J = 4.8 Hz, 2H, CH2N), 3.80 (s, 3H, -OMe); 13C NMR (75 MHz, DMSO-d6): δC = 190.5, 164.5, 164.4, 162.7, 160.3, 147.8, 144.4, 133.1, 131.9, 119.0, 118.9, 116.2, 115.8, 106.8, 101.3, 55.5, 52.0; HRMS-ESI (m/z) Calcd. for C17H16NO6 [M+H]+: 330.0670; found, 330.0664.
1-cyclohexyl-5-(2-hydroxy-4-methoxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4p)
Brown solid, mp 158-161 ℃, yield 58%; 1H NMR (300 MHz, CDCl3): δH = 13.96 (s, 1H, COOH), 12.10 (s, 1H, OH), 8.78 (d, J = 2.2 Hz, 1H, H-6-py), 8.26 (d, J = 2.2 Hz, 1H, H-4-py), 7.42 (d, J = 8.8 Hz, 1H, H-Ar), 6.45 – 6.56 (m, 2H, H-Ar ), 4.84 – 5.14 (m, 1H, CH- cyclohexyl), 3.89 (s, 3H, OMe), 1.89 – 2.14 (m, 4H, H-cyclohexyl), 1.83 (m, 1H, H-cyclohexyl), 1.58 (m, 4H, H-cyclohexyl), 1.18 – 1.35 (m, 1H, H-cyclohexyl); 13C NMR (75 MHz, CDCl3): δC = 192.6, 166.9, 166.2, 164.5, 163.7, 144.2, 142.2, 142.1, 133.4, 119.7, 116.5, 112.1, 108.3, 101.7, 57.1, 55.8, 32.6, 25.6, 25.0; HRMS-ESI (m/z) Calcd. for C20H22NO6 [M+H]+: 372.1292; found, 372.1295.
General procedure for the synthesis of 5a-o
5-(2-hydroxybenzoyl)-1-alkyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (0.2 mmol) and K2CO3 (0.4 mmol,55 mg) were added to an oven-dried flask containing toluene (0.5 mL) and the mixture was refluxed for 8 h. After completing the reaction based on TLC, the mixture was cooled to room temperature. The solvent was evaporated in vacuo, then DCM (15 mL) was added to the crude product and extracted from water (3 × 15 mL). The organic layer was dried over Na2SO4 and evaporated under reduced pressure. The crude product was purified by column chromatography using hexane/EtOAc 3:1 as eluent.
1-benzyl-5-(2-hydroxybenzoyl)pyridin-2(1H)-one (5a)
White crystal, mp 120-121 ℃, yield 86%; 1H NMR (400 MHz, CDCl3): δH = 11.43 (s, 1H,OH), 7.92 (d, 1H, J = 2.2 Hz, H-6-py), 7.76 (dd, 1H, J = 9.4, 2.2 Hz, H-4-py), 7.48 (t, 1H, J = 7.7 Hz, H-Ar), 7.32 – 7.42 (m, 6H, H-Ar), 7.04 (d, 1H ,J = 8.3 Hz, H-Ar), 6.83 (t, 1H, J = 7.5 Hz, H-Ar), 6.66 (d, 1H, J = 9.5 Hz, H-3-py), 5.19 (s, 2H, –CH2N); 13C NMR (100 MHz, CDCl3): δC = 195.1, 162.4, 162.1, 143.2, 139.0, 136.2, 135.3, 131.5, 129.2, 128.6, 128.5, 120.2, 118.8, 118.9, 118.7, 117.3, 52.6; HRMS-ESI (m/z) Calcd. for C19H16NO3 [M+H]+: 306.1135; found, 306.1138.
1-allyl-5-(2-hydroxybenzoyl)pyridin-2(1H)-one (5b)
White crystal, mp 128-129 ℃, yield 88%; 1H NMR (300 MHz, CDCl3): δH = 11.43 (s, 1H, OH), 7.93 (d, 1H, J = 2.3 Hz, H-6-py), 7.75 (dd, 1H, J = 9.5, 2.6 Hz, H-4-py), 7.44 – 7.59 (m, 2H, , H-Ar), 7.08 (d, 1H, J = 8.3 Hz, H-Ar), 6.93 (t, 1H, J = 7.6 Hz, H-Ar), 6.64 (d, 1H, J = 9.5 Hz, H-3-py), 5.91 – 6.06 (m, 1H, CHCH2), 5.36 (d, 1H, J = 10.1 Hz, CH2=CH cis), 5.29 (d, 1H, J = 17.1 Hz, CH2=CH trans), 4.64 (d, 2H, J = 5.8 Hz, CH2N); 13C NMR (75 MHz, CDCl3): δC = 195.1, 162.5, 161.7, 142.9, 139.0, 136.5, 131.5, 120.1, 120.0, 119.8, 118.9, 118.8, 118.7, 117.3, 51.7; HRMS-ESI (m/z) Calcd. for C15H14NO3 [M+H]+: 256.0960; found, 256.0964.
1-cyclohexyl-5-(2-hydroxybenzoyl)pyridin-2(1H)-one (5c)
Yellow crystal, mp 115-116 ℃, yield 83%; 1H NMR (300 MHz, CDCl3): δH = 11.49 (s, 1H, OH), 8.00 (d, 1H, J = 2.5 Hz, H-6-py), 7.73 (dd, 1H, J = 9.5, 2.6 Hz, H-4-py), 7.50 – 7.60 (m, 2H, H-Ar), 7.08 (d, 1H, J = 7.8 Hz, H-Ar), 6.95 (dt, 1H, J = 8.4, 1.2 Hz, H-Ar), 6.61 (d, 1H , J = 9.5 Hz, H-3-py), 4.91 (m, 1H, CH, CH- cyclohexyl), 2.04 – 1.36 (m, 10H, H-cyclohexyl);13C NMR (75 MHz, CDCl3): δC = 195.4, 162.5, 161.7, 139.9, 138.1, 136.0, 131.5, 119.6, 118.9, 118.8, 118.7, 117.1, 54.8, 32.6, 25.7, 25.2; HRMS-ESI (m/z) Calcd. for C18H20NO3 [M+H]+: 298.1540; found, 298.1533.
1-(furan-2-ylmethyl)-5-(2-hydroxybenzoyl)pyridin-2(1H)-one (5d)
Yellow solid, mp 127-128 ℃, yield 68%; 1H NMR (400 MHz, CDCl3): δH = 11.46 (s, 1H, OH), 7.99 (d, 1H ,J = 2.2 Hz, H-6-py), 7.77 (dd, 1H, J = 9.5, 2.4 Hz, H-4-py), 7.50 (t, 2H, J = 8.0 Hz, H-Ar), 7.43 (d, 1H, J = 1.8 Hz, H-furyl ), 7.07 (d, 1H, J = 8.2 Hz, H-Ar), 6.90 (t, 1H, J = 7.6 Hz, H-Ar), 6.64 (d, 1H, J = 9.5 Hz, H-3-py), 6.51 (d, 1H, J = 3.0 Hz, H-furyl), 6.36 – 6.42 (m, 1H, H-furyl), 5.18 (s, 2H, CH2N);13C NMR (100 MHz, CDCl3): δC =195.1, 162.5, 161.7, 147.8, 143.6, 142.9, 139.1, 136.2, 131.7, 120.2, 118.9, 118.8, 118.7, 117.3, 111.1, 111.0, 45.1; HRMS-ESI (m/z) Calcd. for C17H14NO4 [M+H]+: 296.0931; found, 296.0921.
5-(2-hydroxybenzoyl)-1-(prop-2-yn-1-yl)pyridin-2(1H)-one(5e)
White solid, mp 117-116 ℃, yield 68%; 1H NMR (400 MHz, CDCl3): δH = 11.46 (s, 1H, OH), 8.35 (d, 1H, J = 2.4 Hz , H-6-py), 7.82 (dd, 1H , J = 9.5, 2.5 Hz, H-4-py), 7.56 – 7.62 (m, 1H, H-Ar), 7.56 – 7.49 (m, 1H, H-Ar), 7.09 (d, 1H, J = 8.3 Hz,H-Ar), 6.94 (t, 1H, J = 7.5 Hz, H-Ar), 6.65 (d, 1H , J = 9.5 Hz, H-3-py), 4.83 (d, 2H, J = 2.5 Hz, CH2N), 2.61 (t, 1H, J = 2.5 Hz, CH≡C); 13C NMR (100 MHz, CDCl3): δC = 195.1, 162.4, 162.1, 141.7, 139.4, 136.7, 136.3, 131.6, 129.0, 119.7, 118.9, 118.8, 117.5, 75.8, 38.5; HRMS-ESI (m/z) Calcd. for C15H12NO3 [M+H]+: 254.0610; found, 254.0601.
5-(2-hydroxybenzoyl)-1-(1-phenylethyl)pyridin-2(1H)-one (5f)
Yellow solid, mp 95-97 ℃, yield 87%; 1H NMR (400 MHz, CDCl3): δH = 11.42 (s, 1H, OH), 7.77 (d, 1H, J = 2.5 Hz, , H-6-py), 7.70 – 7.73 (m, 1H , H-4-py ), 7.33 – 7.48 (m, 6H, H-Ar), 7.11 (dd, 1H , J = 8.0, 1.4 Hz, H-Ar), 7.01 (d, 1H , J = 8.0 Hz, H-Ar), 6.68 (t, 2H, J = 8.0 Hz, H-Ar, H-3-py ), 6.46 (q, 1H, J = 7.0 Hz, CHN), 1.74 (d, 3H, J = 7.0 Hz, CH3); 13C NMR (100 MHz, CDCl3): δC = 194.9, 162.4, 161.8, 141.1, 139.2, 138.2, 135.9, 131.3, 129.2, 128.5, 127.5, 120.0, 118.7, 118.6, 118.5, 117.1, 53.7, 18.9; HRMS-ESI (m/z) Calcd. for C20H18NO3 [M+H]+: 320.1393; found, 320.1397.
1-benzyl-5-(5-fluoro-2-hydroxybenzoyl)pyridin-2(1H)-one (5j)
Yellow solid, mp 105-106 ℃, yield 84%; 1H NMR (300 MHz, CDCl3): δH = 11.08 (s, 1H, OH), 7.93 (d, 1H, J = 2.4 Hz, H-6-py), 7.76 (dd, 1H, J = 9.5, 2.6 Hz, , H-4-py), 7.32 – 7.45 (m, 5H, H-Ar), 7.19 – 7.27 (m, 1H, H-Ar), 7.08 (dd, 1H, J = 8.7, 3.0 Hz, H-Ar), 7.02 (dd, 1H, J = 9.1, 4.5 Hz, H-Ar), 6.68 (d, 1H, J = 9.5 Hz, , H-3-py), 5.20 (s, 2H, CH2N); 13C NMR (75 MHz, CDCl3): δC = 194.0, 161.9, 158.5, 154.6 (1JCF = 240.0 Hz), 143.2, 138.5, 135.1, 129.3, 128.7, 128.5, 123.5 (2JCF = 23.6 Hz), 120.4, 120.0 (3JCF = 6.0 Hz), 118.3 (3JCF = 6.1 Hz), 116.8, 116.4 (2JCF = 24.0 Hz), 52.6; HRMS-ESI (m/z) Calcd. for C19H15FNO3 [M+H]+: 324.1014; found, 324.1012.
1-allyl-5-(5-fluoro-2-hydroxybenzoyl)pyridin-2(1H)-one (5k)
Yellow solid, mp 100-101 ℃, yield 78%; 1H NMR (300 MHz, CDCl3): δH = 11.12 (s, 1H, OH), 7.96 (d, 1H , J = 2.5 Hz, H-6-py), 7.77 (dd, 1H, J = 9.5, 2.5 Hz, H-4-py), 7.16 – 7.33 (m, 2H, H-Ar), 7.06 (dd, 1H, J = 8.9, 4.6 Hz, H-Ar), 6.66 (d, 1H, J = 9.5 Hz, H-3-py), 5.89 – 6.09 (m, 1H, CHCH2), 5.35 – 5.41 (m, 1H, =CH cis), 5.30 (dd, 1H, J = 16.0, 0.9 Hz, =CH trans), 4.65 (d, 2H, J = 6.0 Hz, CH2N); 13C NMR (75 MHz, CDCl3): δC = 194.1, 161.6, 158.5, 154.7 (1JCF = 239.5 Hz), 143.1, 138.6, 131.5, 131.4, 123.6 (2JCF = 23.7 Hz), 120.2, 120.1 (3JCF = 6.5 Hz), 118.4 (3JCF = 6.4 Hz), 116.8, 116.5 (2JCF = 24.3 Hz), 51.7; HRMS-ESI (m/z) Calcd. for C15H13FNO3 [M+H]+: 274.0825; found, 274.0820.
1-cyclohexyl-5-(5-fluoro-2-hydroxybenz-oyl)pyridin-2(1H)-one (5l)
Yellow solid, mp 125-126 ℃, yield 78%; 1H NMR (300 MHz, CDCl3): δH = 11.17 (s, 1H, OH), 8.02 (d, 1H, J = 2.5 Hz, H-6-py), 7.72 (dd, 1H, J = 9.5, 2.6 Hz, H-4-py), 7.18 – 7.34 (m, 2H, H-Ar), 7.06 (dd, 1H, J = 9.0, 4.6 Hz, H-Ar), 6.62 (d, 1H, J = 9.5 Hz, H-3-py), 4.81 – 4.98 (m, 1H, CH- cyclohexyl), 1.11 – 2.07 (m, 10H, H-cyclohexyl); 13C NMR (75 MHz, CDCl3): δC = 194.3, 161.6, 158.6, 158.5, 154.7 (1JCF = 239.6 Hz), 140.1, 137.8, 123.4 (2JCF = 23.6 Hz), 120.1 (3JCF = 6.0 Hz), 119.7, 118.5 (3JCF = 6.3 Hz), 116.5 (2JCF = 23.8 Hz), 54.9, 32.6, 25.7, 25.2; HRMS-ESI (m/z) Calcd. for C18H19FNO3 [M+H]+: 316.1212; found, 316.1207.
1-benzyl-5-(2-hydroxy-4-methoxybenzoyl)pyridin-2(1H)-one (5o)
Brown solid, mp 83-85 ℃, yield 60%; 1H NMR (400 MHz, CDCl3): δH = 12.20 (s, 1H, OH), 7.86 (d, 1H, J = 2 Hz, H-6-py), 7.71 (dd, 1H, J = 9.5, 2.2 Hz, H-4-py), 7.29 – 7.43 (m, 6H, H-Ar), 6.66 (d, 1H, J = 9.5 Hz, H-3-py), 6.49 (d, 1H, J = 2.1 Hz, H-Ar), 6.37 (dd, 1H , J = 8.9, 2.2 Hz, H-Ar), 5.20 (s, 2H, CH2N), 3.85 (s, 3H, OCH3); 13C NMR (100 MHz, CDCl3): δC= 193.7, 166.2, 165.8, 162.1, 142.2, 139.0, 135.4, 133.3, 129.2, 128.6, 128.5, 120.2, 117.7, 112.5, 107.6, 101.4, 55.7, 52.5; HRMS-ESI (m/z) Calcd. for C20H18NO4 [M+H]+: 336.1015; found, 336.1010.
General procedure for the synthesis of 1-benzyl-2-oxo-1,2-dihydropyridine-3-carbo-xylic acid (6) (36)
Compound 2-chloro-1,2-dihydropyridine-3-carboxylic acid (1 mmol) in 70% aqueous acetic acid (10 mL) was heated under reflux for 4-6 h (see ref 5 in article). Completion of the reaction was checked by TLC. After cooling a solid product precipitated which was filtered, washed well with water, dried and purified by recrystallization from DMF. Compound 2-oxo-1,2-dihydropyridine-3-carboxylic acid (1 equiv) in DMF (4 mL) BnBr (1.3 equiv) and potassium carbonate (1.5 equiv) were added. The reaction mixture was stirred at room temperature during 20-50 h. After completion (checked by TLC) the reaction mixture was poured into ice-water (25 mL) and the solid product formed was filtered, washed well with water, dried and purified by recrystallization from EtOH.
1-benzyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (6)
White solid, mp 128-130 ℃, yield 67%; 1H NMR (300 MHz, DMSO-d6): δH = 14.46 (s, 1H, COOH), 8.42-8.36 (m, 2H, H-4,6-py), 7.40-7.27 (m, 5H, Bn), 6.76 (t, J = 6.8 Hz, 1H, H-5-py), 5.31 (s, 2H, -CH2); 13C NMR (75 MHz, , DMSO-d6): δC = 164.72, 163.6, 145.6, 145.1, 135.8, 128.8, 128.1, 127.9, 116.9, 108.8, 52.6.
General procedure for the preparation of Methyl 1-benzyl-5-(2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylate(7)
Compound 4a (1mmol) in DMF (4 mL) were added methyl iodide (1 mmol) and potassium carbonate (1.5 mmol). The reaction mixture was stirred at rt for 2.5 days. Water was added and the reaction mixture was extracted with hexanes-ether (1:1) solvent system. The combined organic phases were dried over Na2SO4, filtered, and concentrated in a vacuum to yield 8a (40%) as an orange solid.
Red solid, mp 150-152 ℃, yield 60%; 1HNMR (300 MHz, CDCl3): δH = 8.49 (d, J = 2.6 Hz, 1H, H-6-py), 8.16 (d, J = 2.6 Hz, 1H, H-4-py), 7.45 (t, J = 7.5 Hz, 1H, H-Ar), 7.36-7.29 (m, 6H, H-Ar), 7.01 (t, J = 7.5 Hz, 1H, H-Ar), 6.91 (d, J = 8.4 Hz, 1H, H-Ar), 5.15 (s, 2H, CH2N), 3.85 (s, 3H, CH3), 3.60 (s, 3H, CH3), 13CNMR (75 MHz, CDCl3): δC = 190.4, 165.0, 159.0, 156.6, 147.3, 144.2, 134.9, 132.8, 129.8, 129.0, 128.5, 126.8, 121.1, 119.3, 116.8, 111.3, 55.4, 53.3, 53.4; HRMS-ESI (m/z) C22H20NO5 [M+H]+ : 378.1341; found, 378.1349.
Ethyl 1-benzyl-5-(2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylate (8)
White solid, mp 115-117 ℃, yield 73%; 1HNMR (600 MHz, CDCl3): δH = 11.38 (s, 1H, OH), 8.53 (s, 1H, H-6-py), 8.14 (s, 1H, H-4-py), 7.53 (t, J = 7.6 Hz, 1H, H-Ar), 7.43 – 7.37 (m, 6H, H-Ar), 7.09 (d, J = 8.4 Hz, 1H, H-Ar), 6.88 (t, J = 7.7 Hz, 1H, H-Ar), 5.26 (s, 2H, CH2N), 4.42 (q, J = 7.2 Hz, 2H, CH2O), 1.41 (t, J = 7.2 Hz, 3H, CH3CH2); 13CNMR (151 MHz, CDCl3): δC = 194.3, 164.1, 162.6, 158.7, 146.1, 143.6, 136.5, 134.8, 131.4, 129.3, 128.9, 128.8, 120.5, 119.0, 118.9, 118.5, 115.9, 61.7, 53.3; HRMS-ESI (m/z) C22H20NO5 [M+H]+ : 378.1278; found, 378.1273.
Antimicrobial assay
All new structures were assessed to in vitro tests for their antibacterial properties. The antibacterial activities were evaluated against E. coli PTCC 25922, A. baumannii (clinical strain); S. aureus ATCC 1431; C. albicans ATCC 10231 and Methicillin-resistant S. aureus (clinical strain).
The values of minimum inhibitory concentration (MIC) were assayed by the standard technique described by CLSI (37) meaning standard broth micro-dilution procedure.
The culture of each strain was prepared on a nutrient agar plate and remained overnight, then, it was used to make the bacterial suspensions equal to 0.5 McFarland standards in sterile normal saline. Then Serial dilutions of samples were obtained in sterile 96 wells plates containing Mueller–Hinton broth which was prepared with concentrations ranging from 0.031 to 64 mg/ml. The final concentration of bacterial cells in each well was 0.5–1 ×106 cfu mL-1 approximately.
Minimum inhibitory concentrations (MICs) were recorded after 22 hours of incubation at 37 ºC. Each experiment was performed in triplicate. Cefixime, Ciprofloxacin and Nystatin were used as the reference antibiotics for bacteria and yeast, respectively.
Molecular modeling procedure
Target enzyme and ligand preparation
To find out the interactions mode of designed molecules over DNA gyrase, the Maestro Molecular Modeling platform (version 10.5) by Schrödinger, LLC was performed (38). The X-ray crystallographic structure of S. aureus DNA gyrase (in complex with moxifloxacin and DNA) was downloaded from the Protein Data Bank (PDB ID; 5cdq) (www.rcsb.org) (39).
As urease is reported to be functionally active in a monomeric state, all the docking studies were performed on a single monomer. In addition, prosthetic group and co-factors are not directly involved in urease inhibition, so they were removed before docking investigation. Water molecules and co-crystallized ligands were removed from the enzyme’s crystallographic structures.
The 2D structures of all synthesized compounds were drawn in Marvin 15.10.12.0 program (http://www.chemaxon.com) (40) and converted into a pdb file. The Protein Preparation Wizard (41) and the LigPrep (42) module were used to prepare protein and ligand structure properly. The missing side chains of the proteins were filled using the Prime tool and missing residues were updated.
Induced fit docking (IFD) protocol
IFD method implemented in Glide software (Schrödinger LLC 2018, USA) was used to investigate the possible binding mode of the most active inhibitors in the active site of DNA gyrase (38). The moxifloxacin binding site was used to generate the grid for IFD calculation. The maximum 20 poses with receptor and ligand van der Waals radii of 0.7 and 0.5, respectively considered. Residues within 5 Å of the moxifloxacin at the active site were refined followed by side-chain optimization. Structures whose Prime energy is more than 30 kcal/mol are eliminated based on extra precious Glide docking.
Molecular dynamic (MD) simulation
Molecular simulations of this study were performed using the Desmond v5.3 using the Maestro interface (from Schrödinger 2018‐4 suite) (43). The appropriate pose for the MD simulation procedure of the compound was achieved by the IFD method. To build the system for MD simulation, the protein-ligand complexes were solvated with SPC explicit water molecules and placed in the center of an orthorhombic box of appropriate size in the periodic boundary condition. Sufficient counter‐ions and a 0.15 M solution of NaCl were also utilized to neutralize the system and to simulate the real cellular ionic concentrations, respectively. The MD protocol involved minimization, pre-production, and finally production MD simulation steps. In the minimization procedure, the entire system was allowed to relax for 2500 steps by the steepest descent approach. Then the temperature of the system was raised from 0 to 300 K with a small force constant on the enzyme to restrict any drastic changes. MD simulations were performed via NPT (constant number of atoms, constant pressure i.e. 1.01325 bar and constant temperature i.e. 300 K) ensemble. The Nose‐Hoover chain method was used as the default thermostat with 1.0 ps interval and Martyna‐Tobias‐Klein as the default barostat with 2.0 ps interval by applying an isotropic coupling style. Long‐range electrostatic forces were calculated based on the particle‐mesh‐based Ewald approach with the cut‐off radius for columbic forces set to 9.0 Å. Finally, the system was subjected to produce MD simulations for 20 ns for each protein-ligand complex. During the simulation was stored every 1000 ps of the actual frame. The dynamic behavior and structural changes of the systems were analyzed by the calculation of the root mean square deviation (RMSD) and RMSF. Subsequently, the energy-minimized structure calculated from the equilibrated trajectory system was evaluated for the investigation of each ligand-protein complex interaction.
In-silico ADME properties of synthesized compounds
QikProp module of Schrodinger was applied to calculate the important pharmacokinetic properties of the synthesized compounds like drug-likeness, metabolism and cell permeation (44).

Results and Discussion

Synthesis and chemistry
According to our previously published research (25), at first 2-pyridone-3-carboxylic acid 4a was synthesized through a three-component reaction of 3-formylchromone 1, Meldrum’s acid 2, and benzylamine 3a. To find the best reaction conditions, diammonium hydrogen phosphate (DAHP) was examined as a basic catalyst of this reaction at different temperatures in different solvents. Correspondingly, as shown in Scheme 1, DAHP 20 mol% in water at 70 °C was selected as the optimized reaction conditions (Scheme 2) to develop the diversity of the products 4a-p by the use of various aliphatic or aromatic amines 3a-i (Table 1). Compared to our previous publication (25), in the current study, some variations were applied including the use of different amines having propargyl, triazole and phenyl rings, and 3-formyl-chromenes having OMe and F substitution on its ring.
Next, we focused on the decarboxylation of the prepared 2-pyridone-3-carboxylic acids 4a-p. Compound 4a was chosen for the reaction optimization. Solvent, temperature, and the base were systematically varied (Table 2). Among the tested bases (entries 1-6), K2CO3 and Ag2CO3 gave the highest yields of 46 and 56%, respectively. According to the efficient amount, cost and availability, K2CO3 was used to find the solvent and the optimized heating. Correspondingly, the best result was attained using K2CO3 as the base by increasing its amounts and running the reaction in toluene at 80 °C for 5 hours to afford the decarboxylated 2-pyridone 5a in 86% yield (entry 10). Therefore, some 2-pyridone-3-carboxylic acids 4a-p were treated in these conditions (Scheme 3), and their corresponding decarboxylated products were produced in moderate to high yields (Table 3).
To propose a reasonable reaction mechanism, we used two 2-pyridone derivatives 6 and 7 as substrates in decarboxylation reaction. The effective role of the hydroxyl group through the decarboxylation reaction was studied using the deoxy derivative of 1-benzyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid 6 and OH-protected compound of methyl 1-benzyl-5-(2-methoxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 7 (Scheme 4), and no decarboxylated product was detected confirming the hydroxyl group is important for decarboxylation process. Thus, we concluded that this reaction may proceed via Krapcho decarboxylation (45). To confirm our proposed mechanism passing from Krapcho decarboxylation, ethyl 1-benzyl-5-(2-hydroxybenzoyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 8 was treated under the optimized conditions (Scheme 5), and the desired product 9 was isolated in 30% yield. This demonstrates that both carboxylic acid and ester groups on 2-pyridone are decarboxylated in the presence of K2CO3 that is because of an electron-withdrawing group in the beta position (Krapcho condition).
A plausible mechanism of the decarboxylation of 2-pyridone-3-carboxylic acids has been shown in Scheme 6. K2CO3 acts as the base to react with the protons of hydroxyl and carboxylic acid groups in compound 4, then, oxa-Michael addition of phenoxy anion 10 gives intermediate 11. Since toluene solvent is not dry, its moisture accelerates the proton transfer to promote this reaction. Furthermore, because just one molecule is divided into two, it increases the entropy accompanying by releasing heat, thus elimination of CO2 is a preferable driving force. Consequently, intermediate 11 can participate in Krapcho decarboxylation (45), passing from 12, C-O bond is broken following protonation the decarboxylated product 5 is formed.
Biological activity evaluation
Antimicrobial assay
In this study, the antimicrobial activity of compounds was assessed against two Gram-positive (S. aureus PTCC 1431 and Methicillin-resistant S. aureus (MRSA) (clinical strain) and two Gram-negative bacteria strains (E. coli PTCC 25922 and A. baumannii (clinical strain) and C. albicans ATCC 10231. The MIC values of the screened compounds were compared with cefixime, ciprofloxacin, and nystatin as the standard antibacterial agents and listed in Table 4.
In the case of Gram-negative bacteria, compound 4h showed the best antibacterial activity against E. coli with MIC value of 12.79 µg/mL and compounds 5f and 5j were showed moderate anti-E. coli effect with MIC value of 159.68 and 161.66 µg/mL, respectively.
Furthermore, compounds 4m, 4n, 4o, 5b, 5c and 5d recorded moderate inhibitory effects against Acinetobacter, which is one of the most important human pathogenic.
Based on the result, it was observed that the synthesized compound has higher inhibition activity over S. aureus. In other words, compounds 4b, 4j, 4n, 4o, 4p, 5a, 5b and 5c represented significant higher antibacterial activity against S. aureus strain with MIC values of 4.67, 5.73, 5.92, 10.29, 2.32, 9.5, 3.2 and 2.32 µg/mL, respectively.
As can be seen, none of the compounds showed comparable or more activity determined by C. albicans against nystatin, and only compounds 5c and 5l with MIC values of 279.32 and 315.34 µg/ml, respectively, revealed better results than the other compounds. The introduction of the 4-methoxy substituent at the R2 position of the template structure with carboxylic acid led to a significant increase in the antibacterial activity of this compound against S. aureus like compounds 4n, 4o, and 4p.
Reliability of the docking protocol
The reliability of the applied docking protocol was assessed by re-docking of moxifloxacin into the active site of DNA gyrase. The RMSD of the docked binding mode compared with the crystallographic binding mode. The reliability of the docking procedure was considered successful if the RMSD is below 2.0 Å. Figure 2 shows the superposed structures between the docked and the crystallographic moxifloxacin over DNA gyrase, which has an acceptable value within the cutoff limit (2.23 Å). Then, this protocol was similarly applied to all synthesized compounds (4a-4p and 5a-5o).
Figure 2 depicts the docked moxifloxacin intercalates into DNA at the nicks introduced by the topoisomerases and that the pyrrolo[3,4-b]pyridine moiety at C-7 of ring system interacts with the GyrB subunit. The distal nitrogen atom of the pyrrolo[3,4-b]pyridine moiety at the C-7 ring system lies close to Glu477 in S. aureus GyrB, whereas the 3-carboxyl end of the moxifloxacin interacted to Ser84 located at the GyrA subunit, through a magnesium-water bridge hydrogen bond with 1.4 Å distance that stabilizes the drug-enzyme DNA complex (46). In summary, Moxifloxacin bounds in the DNA at the cleavage sites making specific interactions with the protein and inhibiting DNA relegation (47).
Investigating molecular docking interaction of the synthesized compounds
The performed docking procedure was then applied to evaluate the interactions between newly synthesized compounds; 4a-4p and 5a-5o over the DNA gyrase active site. The top IFD scoring pose of all compounds was analyzed inside the binding site of DNA gyrase.
Figures 3a and 3b show the quinolone ring moiety of ciprofloxacin and moxifloxacin intercalated between the DNA base pairs through π-π hydrophobic interaction with DG9 and DA13. In addition, the 4-oxo-3-carboxylic acid groups of the quinolone nucleus tightly coordinated along with the Mg ion and further stabilized by H-bond interaction with Ser84 (with 1.6 Å and 1.2 Å, respectively) located at the α-helix IV of GyrA while the tail part at the C-7 of the quinolone ring system of both compounds (7-piperazine and 7-pyrrolo[3,4-b]pyridin group) faced to the GyrB subunit.
The docked conformation of compounds 4j, 4n, 4p revealed that they all have the same orientation in which they intercalated into the DNA and pointed toward the Mg ion through 2-oxo and 3-carboxylic groups. Furthermore, the N-alkyl moiety faced the GyrA α-helix (yellow helix), while the 3,4-disubstituted phenol ring closed to the GyrB subunit (blue helix) (Figure 3c).
Figure 3d represents the cross-link orientation of compound 4p over the cleaved complex of DNA gyrase, in which the 2-hydroxy-4-methoxybenzoyl interacted with Arg458 and Asp437 through π-cation and H-bond, respectively, while the bulky N-cyclohexane and the 4-carbonyl groups occupied in the proximity of Gly81 and formed H-bond interaction with Ser84, (1.6 Å), respectively. Comparing the orientation of compound 4p with the well-known inhibitors (Figures 3a and 3b), revealed that the 2-hydroxy-4-methoxybenzoyl has the same location and orientation as the 7-piperazine and 7-pyrrolo[3,4-b]pyridin groups of ciprofloxacin and moxifloxacin, respectively. In addition, the electron-donating property of the methoxy substitution at the benzoyl ring increases the tendency of the compound 4p to make π-cation interaction with Arg458 in which stabilized the cleaved complex. This may propose the reason why compounds 4n, 4o, and 4p with 4-methoxy group represent higher S. aureus inhibition activity.
Same as the compounds in the 4th series, compounds 5a, 5b, and 5c overlay in an identical location and orientation and stabilized the cleaved complex through cross-linking the GyrA and GyrB subunits by intercalating the DNA fragment (Figure 3e). Although the 3-carboxyl group was omitted, the hydroxyl and carbonyl groups of 2-hydroxybenzoyl moiety oriented toward the Mg ion and further stabilized to the GyrA through H-bond interaction with Ser84. As a result of Figure 3f observation, the 2-pyridone ring closed to the GyrA α-helix (yellow helix) and formed H-bond with Gly82 (2.4 Å), while the related N-alkyl group twisted back and faced toward the GyrB subunit (blue helix) surrounded by Ser438 and Gly436. In summary, the docking results revealed the mentioned active compounds successfully intercalated the DNA gate region of the cleaved complex through cross-linking the GyrA and GyrB subunits of DNA gyrase like as ciprofloxacin and moxifloxacin.
Molecular dynamic investigation
To understand the criteria for rational designing of gyrase inhibitors, it is necessary to uncover the structural perturbations incurred by the most potent compounds (4p, 5c) over DNA gyrase and the effect of these compounds on the DNA gate environment in comparison to ciprofloxacin as DNA gyrase standard inhibitor.
Root mean square deviation (RMSD) of the protein’s Cα from its initial to final conformation applied over 20 ns MD simulation to study the stability of the protein-ligand complex. The RMSD values of gyrase-ligand complexes indicate that the employed simulation time has been enough to obtain an equilibrium structure (Figure 4). Thus, the structure at the MD equilibrium state was used to investigate the structural specificity of the ligand-protein complexes. The RMSD simulation showed that gyrase makes a complex with ciprofloxacin maintained overall stability after 5 ns of MD simulation time with higher fluctuation stabilizing at an average of 2 Å (Figure 4, green line), while the bounded-state of compounds 4p and 5c displayed equilibration with obviously higher fluctuations (2.6 Å and 2.73 Å for the complex of 4p-DNA gyrase and 5c-DNA gyrase, respectively) 3 red and orange lines.
Based on the MD equilibrium state, ciprofloxacin stabilized at the DNA gate domain and formed H-bond with Ser84 and Asp437 through both the head carboxylate and the tail N atom of piperazine part of the molecule for about 34% and 84% of simulation time, respectively (Figure 5a). Figures 5b and 5c show compound 4p and 5c tightly interacted with Glu88 by the carboxylic group and the 2-hydroxyl benzoyl moiety through Mg coordination and H-bond interaction, respectively for the significant amount of MD simulation time. In addition, like ciprofloxacin, Asp437 at GyrB subunit provided water-mediated H-bond with 2-hydroxy benzoyl moiety of compound 4p for about 30% of MD simulation time, while in the case of compound 5c Arg458 provided H-bond interaction with the 2-carboxy group of pyrimidone for about 38% of MD simulation time along.
It is noteworthy that compounds 4p and 5c represent primary interaction as with fluoroquinolones with DNA gyrase through water-mediated and metal ion-bridge to Ser84, Glu88 from GyrA subunit and Arg458 and Asp437 located at GyrB subunit, which is the key residues in the DNA gate region of DNA gyrase.
Ligand interacting with these residues at the GyrA and GyrB interface seems to be the most important for stabilizing the cleaved complex and may cause antibacterial activity through DNA gyrase inhibition (47, 48). Furthermore, Ser84 and Glu88 in S. aureus are the most commonly mutated in clinical isolates resistant to fluoroquinolones, which propose the reason why compounds provided lower activity over methicillin-resistant S. aureus (49).
In-silico ADME properties of the most active synthesized compounds
QikProp module of Schroedinger was used to calculate the essential pharmacokinetic properties including drug-likeness, metabolism, cell permeation, and bioavailability of the synthesized compounds.
Table 5 shows the “drug-likeness” of the synthesized compounds based on the “Lipinski rule of five”. It depicts there are no ROF violations and the synthesized compounds show a high probability of finding drug-like potential within these series. Furthermore, the absorption procedure, which affects the bioavailability of a compound, relies on the solubility and permeability of the compound (50).
The computed parameter including the predicted aqueous solubility (log Swat), the predicted % human oral absorption (%HOA), and compliance to Jϕrgensen’s famous “Rule of Three” (RO3) were measured (Table 6). According to Table 6, it was observed that all of the predicted descriptors are in acceptable value (51), which indicates the applied modification could emerge as a good candidate for drug discovery.
The new molecular hybridization of 2-salicyloyl and 2-pyridones
Figure 1

The new molecular hybridization of 2-salicyloyl and 2-pyridones

3D representation of moxifloxacin over DNA gyrase active site. Co-crystallized moxifloxacin and the corresponding re-docked form represented in green and cyan color, respectively. GyrA and GyrB subunit of DNA gyrase are in yellow and blue, respectively
Figure 2

3D representation of moxifloxacin over DNA gyrase active site. Co-crystallized moxifloxacin and the corresponding re-docked form represented in green and cyan color, respectively. GyrA and GyrB subunit of DNA gyrase are in yellow and blue, respectively

3D representation of the modeled cleaved complex consisting of the best IFD pose interaction of compounds over DNA gyrase. The studied compounds include; ciprofloxacin (a), moxifloxacin (b) the superposed compounds <b>4j</b>, <b>4n</b>, <b>4p</b> (c), compound <b>4p</b> (d), the superposed compounds <b>5a</b>, <b>5b</b>, <b>5c</b> (e), and compound <b>5c </b>(f). GyrA and GyrB subunit of DNA gyrase are in yellow and blue, respectively
Figure 3

3D representation of the modeled cleaved complex consisting of the best IFD pose interaction of compounds over DNA gyrase. The studied compounds include; ciprofloxacin (a), moxifloxacin (b) the superposed compounds 4j, 4n, 4p (c), compound 4p (d), the superposed compounds 5a, 5b, 5c (e), and compound 5c (f). GyrA and GyrB subunit of DNA gyrase are in yellow and blue, respectively

RMSD of the DNA gyrase Cα in complexed with ciprofloxacin (in green) compounds <b>4p</b> (in red) and compound <b>5c</b> (in orange) over 20 ns MD simulation time
Figure 4

RMSD of the DNA gyrase Cα in complexed with ciprofloxacin (in green) compounds 4p (in red) and compound 5c (in orange) over 20 ns MD simulation time

2D representation of ligand-residue interactions that occur during the 30% of simulation time which include DNA gyrase bound-state of ciprofloxacin (a), compound <b>4p</b> (b) and compound <b>5c</b> (c)
Figure 5

2D representation of ligand-residue interactions that occur during the 30% of simulation time which include DNA gyrase bound-state of ciprofloxacin (a), compound 4p (b) and compound 5c (c)

Synthesis of 2-pyridone compounds
Scheme 1

Synthesis of 2-pyridone compounds

Synthesis of 2-pyridone-3-carboxylic acids
Scheme 2

Synthesis of 2-pyridone-3-carboxylic acids

Decarboxylation reaction of 2-pyridone-3-carboxylic acids
Scheme 3

Decarboxylation reaction of 2-pyridone-3-carboxylic acids

Control reaction to confirm the role of the hydroxyl group in decarboxylation
Scheme 4

Control reaction to confirm the role of the hydroxyl group in decarboxylation

Control reaction to confirm Krapcho mechanism
Scheme 5

Control reaction to confirm Krapcho mechanism

The plausible mechanism for decarboxylation of 2-pyridone-3-carboxylic acids
Scheme 6

The plausible mechanism for decarboxylation of 2-pyridone-3-carboxylic acids

Table 1The synthesized 2-pyridone-3-carboxylic acids 4a-p
Table 2Optimizing reaction condition for decarboxylation of 2-pyridone-3-carboxylic acids 4a
Table 3The decarboxylated 2-pyridones 5a-o
Table 4In-vitro antibacterial activities of compounds (4a-p) and (5a-o).
CompoundMinimum inhibitory concentration (MIC µg/mL)
E. coliA. baumanniiS.aureusMRSAC. albicans
4a>500500<349.34349.34>500
4b>500>5004.67>500>500
4c341.36>500>500>500>500
4d>500>500>500>500>500
4e>500>500297.27>500>500
4f>500>500363.37363.37>500
4g>500>500416.39>500>500
4h12.79>500>500>500>500
4i>500>500>500>500>500
4j>500>5005.73367.33>500
4k>500>500>500>500>500
4l>500>500359.35359.35>500
4m>500381.36190.68381.36>500
4n>500379.375.92379.37>500
4o329.31329.3210.2982.33>500
4p371.39>5002.96>500>500
5a305.33>5009.5>500>500
5b510.54510.543.9>500>500
5c297.35297.322.32297.32297.32
5d>500295.2973.82>500>500
5e>500>500>500>500>500
5f159.68>500>500>500>500
5j161.66>500161.66>500>500
5k>500>500>500>500>500
5l>500>50078.83315.34315.34
5o335.36>500167.68>500500>
Cefixime432132-
Ciprofloxacin0.5640.2564-
Nystatin----64
Table 5The Lipinski rule of five properties of the most active compounds
No.MwHBDaHBAbLogP o/wcrotordROFe
4b299.2820.0005.7502.01660
4j367.3330.0005.7503.26060
4n379.3680.0006.5003.11670
4o329.3090.0006.5002.04570
4p371.3890.0006.5002.80650
5a305.3320.0004.7503.14750
5b255.2730.0004.7502.12750
5c297.3530.0004.7502.81630
ciprofloxacn331.3461.0006.0000.28010
Table 6The calculated ADME properties of synthesized compounds
No.LogSwataHOAb (%)MetabcRO3d
4b-2.69571.420
4j-4.21073.120
4n-3.91972.530
4o-2.87062.130
4p-4.28567.820
5a-3.72094.630
5b-2.37288.730
5c-3.88395.620
ciprofloxacin-3.79375.701

Conclusion

New 2-pyridone-3-carboxylic acid deri-vatives were designed and synthesized through a three-component reaction between 3-formylchromone, primary amines, and Meldrum’s acid. Subsequently, a decarboxyl-ation reaction catalyzed by K2CO3 was performed in toluene, and all compounds were screened for their antimicrobial activity. IFD and MD study showed that the most active anti S. aureus are compounds 4p and 5c exhibiting primary interaction as with fluoroquinolones by cross-linking over DNA gyrase active site via metal ion bridge and H-bonding interaction with Ser84 and Glu88 from GyrA subunit along with Arg458 and Asp437 located at GyrB subunit. These interactions seem to be the most important ones for stabilizing the DNA cleaved complex and may cause antibacterial activity through DNA gyrase inhibition.

Acknowledgments

References

  • 1.
    Rampioni G, Leoni L, Williams P. The art of antibacterial warfare: Deception through interference with quorum sensing–mediated communication. Bioorg. Chem. 2014;55:60-8. [PubMed ID: 24823895].
  • 2.
    Surup F, Wagner O, von Frieling J, Schleicher M, Oess S, Müller P, Grond S. The iromycins, a new family of pyridone metabolites from Streptomyces s Structure, NOS inhibitory activity, and biosynthesis. J. Org. Chem. 2007;72:5085-90. [PubMed ID: 17564461].
  • 3.
    Fotiadou AD, Zografos AL. Accessing the structural diversity of pyridone alkaloids: Concise total synthesis of rac-citridone A. Org. Lett. 2011;13:4592-5. [PubMed ID: 21819096].
  • 4.
    Salem MS, Sakr SI, El-Senousy WM, Madkour HMF. Synthesis, antibacterial, and antiviral evaluation of new heterocycles containing the pyridine moiety. Arch. Pharm. 2013;346:766-73.
  • 5.
    Jessen HJ, Gademann K. 4-Hydroxy-2-pyridone alkaloids: structures and synthetic approaches. Nat. Prod. Rep. 2010;27:1168-85. [PubMed ID: 20532354].
  • 6.
    Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson J-PR, Sakata SK, Chen L, Guzman MC, Meador JW, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3c protease inhibitors. 6 Structure−activity;45:1607-23.
  • 7.
    Chand K, Alsoghier HM, Chaves S, Santos MA. Tacrine-(hydroxybenzoyl-pyridone) hybrids as potential multifunctional anti-Alzheimer’s agents: AChE inhibition, antioxidant activity and metal chelating capacity. J. Inorg. Biochem. 2016;163:266-77. [PubMed ID: 27235273].
  • 8.
    Amr A-GE, Abdulla MM. Anti-inflammatory profile of some synthesized heterocyclic pyridone and pyridine derivatives fused with steroidal structure. Bioorg. Med. Chem. 2006;14:4341-52. [PubMed ID: 16545570].
  • 9.
    Lo Presti E, Boggia R, Feltrin A, Menozzi G, Dorigo P, Mosti L. 3-Acetyl-5-acylpyridin-2(1H)-ones and 3-acetyl-7,8-dihydro-2,5(1H,6H)-quinolinediones: synthesis, cardiotonic activity and computational studies. Il Farmaco. 1999;54:465-74. [PubMed ID: 10486914].
  • 10.
    Li Q, Mitscher LA, Shen LL. The 2‐pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med. Res. Rev. 2000;20:231-93. [PubMed ID: 10861727].
  • 11.
    Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev. 2005;105:559-92. [PubMed ID: 15700957].
  • 12.
    Wiles JA, Hashimoto A, Thanassi JA, Cheng J, Incarvito CD, Deshpande M, Pucci MJ, Bradbury BJ. Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J. Med. Chem. 2006;49:39-42. [PubMed ID: 16392790].
  • 13.
    Bengtsson C, Lindgren AEG, Uvell H, Almqvist F. Design, synthesis and evaluation of triazole functionalized ring-fused 2-pyridones as antibacterial agents. Eur. J. Med. Chem. 2012;54:637-46. [PubMed ID: 22749393].
  • 14.
    Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ. Small-molecule inhibitors target E coli amyloid biogenesis and biofilm formation. Nat. Chem. Biol. 2009;5:913-9. [PubMed ID: 19915538].
  • 15.
    Strelitz F, Flon H, Asheshov IN. Nybomycin, a new antibiotic with antiphage and antibacterial properties. Proc. Natl. Acad. Sci. U.S.A. 1955;41:620-4. [PubMed ID: 16589716].
  • 16.
    Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents. 2005;26:343-56. [PubMed ID: 16323269].
  • 17.
    Strobel G, Ford E, Worapong J, Harper JK, Arif AM, Grant DM, Fung PC, Chau RMW. Isopestacin, an isobenzofuranone from Pestalotiopsis microspora, possessing antifungal and antioxidant activities. Phytochemistry. 2002;60:179-83. [PubMed ID: 12009322].
  • 18.
    Ezaki N, Koyama M, Shomura T, Tsuruoka T, Inouye S. Pyrrolomycins C, D and E, new members of pyrrolomycins. J. Antibiot. 1983;36:1263-7.
  • 19.
    Jiao J, Sun L, Guo Z, Hou S, Holyst R, Lu Y, Feng X. Antibacterial and anticancer PDMS surface for mammalian cell growth using the Chinese herb extract paeonol(4-methoxy-2-hydroxyacetophenone). Sci. Rep. 2016;6:38973-83. [PubMed ID: 27941867].
  • 20.
    Saulnier S, Ghoteimi R, Mathé C, Peyrottes S, Uttaro JP. 2-(Substituted amino)-8-azachromones from 4, 6-Diaryl-2-pyridones: A synthetic strategy toward compounds of broad structural diversity. J. Org. Chem. 2020;85:11778-93. [PubMed ID: 32871069].
  • 21.
    Prendergast AM, McGlacken GP. Transition Metal Mediated C–H Activation of 2‐Pyrones, 2‐Pyridones, 2‐Coumarins and 2‐Quinolones. Eur. J. Org. Chem. 2018;2018:6068-82.
  • 22.
    Bhattacherjee D, Zyryanov GV, Das P. Recent advances in the synthetic approaches to 2-pyridones (microreview). Chem. Heterocycl. Compd. 2020;56:1152-4.
  • 23.
    Pati TK, Ajarul S, Kundu M, Tayde D, Khamrai U, Maiti DK. Synthesis of functionalized arylacetamido-2-pyridones through ortho-C (sp2)–H-activated installation of olefins and alkynes. J. Org. Chem. 2020;85:8563-79. [PubMed ID: 32574496].
  • 24.
    Singh P, Cairns AG, Adolfsson DE, Ådén Jr, Sauer UH, Almqvist F. Synthesis of densely functionalized N-alkenyl 2-pyridones via benzyne-induced ring opening of thiazolino-fused 2-pyridones. Org. Lett. 2019;21:6946-50. [PubMed ID: 31419146].
  • 25.
    Mehrparvar S, Balalaie S, Rabbanizadeh M, Ghabraie E, Rominger F. An efficient tandem approach for the synthesis of functionalized 2-pyridone-3-carboxylic acids using three-component reaction in aqueous media. Mol. Divers. 2014;18:535-43. [PubMed ID: 24792225].
  • 26.
    Daley RA, Topczewski JJ. Aryl-decarboxylation reactions catalyzed by palladium: Scope and mechanism. Synthesis. 2020;52:365-77.
  • 27.
    Li K, Chen L, Fan YX, Wei Y, Yan SJ. Multicomponent Tether catalysis synthesis of highly functionalized 4-(pyridin-2-ylmethyl)-2-aminopyrroles via cascade reaction is accompanied by decarboxylation. J. Org. Chem. 2019;84:11971-82. [PubMed ID: 31464125].
  • 28.
    Gooßen LJ, Deng G, Levy LM. Synthesis of biaryls via catalytic decarboxylative coupling. Science. 2006;313:662-4. [PubMed ID: 16888137].
  • 29.
    Gooßen LJ, Manjolinho F, Khan BA, Rodriguez N. Microwave-assisted Cu-catalyzed protodecarboxylation of aromatic carboxylic acids. J. Org. Chem. 2009;74:2620-3. [PubMed ID: 19239228].
  • 30.
    Gooßen LJ, Rodríguez N, Melzer B, Linder C, Deng G, Levy LM. Biaryl synthesis via Pd-catalyzed decarboxylative coupling of aromatic carboxylates with aryl halides. J. Am. chem. Soc. 2007;129:4824-33. [PubMed ID: 17375927].
  • 31.
    Huang L, Hackenberger D, Gooßen LJ. Iridium‐catalyzed ortho‐arylation of benzoic acids with arenediazonium salts. Angew. Chem. Int. Ed. 2015;54:12607-11.
  • 32.
    Scheipers I, Koch E, Studer A. Stereoselective palladium-catalyzed decarboxylative γ-arylation of acyclic β,γ-unsaturated carboxylic acids. Org. Lett. 2017;19:1741-3. [PubMed ID: 28332848].
  • 33.
    Jafarpour F, Zarei S, Barzegar Amiri Olia M, Jalalimanesh N, Rahiminejadan S. Palladium-catalyzed decarboxylative cross-coupling reactions: A route for regioselective functionalization of coumarins. J. Org. Chem. 2013;78:2957-64. [PubMed ID: 23445254].
  • 34.
    Honeycutt AP, Hoover JM. Nickel-catalyzed oxidative decarboxylative (hetero) arylation of unactivated C–H bonds: Ni and Ag synergy. ACS Catal. 2017;7:4597-601.
  • 35.
    Poon PS, Banerjee AK, Laya MS. Advances in the Krapcho decarboxylation. J. Chem. Res. 2011;35:67-73.
  • 36.
    Laali KK, Insuasty D, Abonia R, Insuasty B, Bunge SD. Novel quinoline–imidazolium adducts via the reaction of 2-oxoquinoline-3-carbaldehyde and quinoline-3-carbaldehydes with 1-butyl-3-methylimidazolium chloride [BMIM][Cl]. Tetrahedron Lett. 2014;55:4395-9.
  • 37.
    Murray P, Baron E, Jorgensen J, Landry M, Pfaller M. Manual of clinical microbiology. 8th ed. Washington: ASM Press; 2007. 1152 p.
  • 38.
    Schrödinger Release 2018-4: Induced Fit Docking protocol; Glide. LLC, New York, NY, 2018; Prime, Schrödinger, LLC, New York, NY; 2018.
  • 39.
    Chan PF, Srikannathasan V, Huang J, Cui H, Fosberry AP, Gu M, Hann MM, Hibbs M, Homes P, Ingraham K. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. Nat. Commun. 2015;6:1-13.
  • 41.
    Schrödinger Release 2018-4: Protein Preparation Wizard; Epik, Schrödinger, LLC. New York, NY, 2018; Impact, Schrödinger, LLC, New York, NY; Prime, Schrödinger, LLC, New York, NY; 2018.
  • 42.
    Schrödinger Release 2018-4: LigPrep, Schrödinger, LLC. New York, NY; 2018.
  • 43.
    Schrödinger Release 2018-4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY; 2018.
  • 44.
    Schrödinger Release 2018-4: QikProp, Schrödinger, LLC. New York, NY; 2018.
  • 45.
    Krapcho AP, Weimaster JF, Eldridge JM, Jahngen EGE, Lovey AJ, Stephens WP. Synthetic applications and mechanism studies of the decarbalkoxylations of geminal diesters and related systems effected in dimethyl sulfoxide by water and/or by water with added salts. J. Org. Chem. 1978;43:138-47.
  • 46.
    Aldred KJ, McPherson SA, Turnbough Jr CL, Kerns RJ, Osheroff N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic acids Res. 2013;41:4628-39. [PubMed ID: 23460203].
  • 47.
    Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 2010;17:1152-3. [PubMed ID: 20802486].
  • 48.
    Srikannathasan V, Wohlkonig A, Shillings A, Singh O, Chan PF, Huang J, Gwynn MN, Fosberry AP, Homes P, Hibbs M. Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide. Acta Crystallogr. Sect. F. 2015;71:1242-6.
  • 49.
    Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53:1565-74. [PubMed ID: 24576155].
  • 50.
    Van De Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2003;2:192-204.
  • 51.
    Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 2002;54:355-66. [PubMed ID: 11922952].
Import into EndNoteImport into BibTex
Crossmark
Crossmark
Checking
Share on
Comments
Number of Comments:0
Cited by
Metrics
Get Permission (article level)

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles

Related Article in PubMed

Related Article in Google Scholar

Create Citation Alert via Google Reader